Arctic Bioscience — Report Publication Announcement 2021

Apr 7, 2022

Arctic Bioscience publishes 2021 annual report

Arctic Bioscience publishes 2021 annual report

Arctic Bioscience AS has today released its Annual Report 2021, including the

Board of Directors report and financial statements. The report and annual

accounts were approved by the Board of Directors after close of business on 6

April 2022.

The report is attached to this stock exchange notice and available on the

company website (https://arctic-bioscience.com/investors/reports

-presentations/).

At 12:00 CEST today, the company will host a webcast to present the annual

report and full year 2021 results, followed by a Q&A.

Webcast Details:

Arctic Bioscience AS FY 2021 webcast presentation:

Date: Thursday April 7, 2022

Time: 12.00 CEST

Format: Webcast and Q&A

Language: English

Link:  https://streams.eventcdn.net/arcticbioscienceas/financial-results-fy

-2021 (https://www.google.com/url?q=https%3A%2F%2Fstreams.eventcdn.net%2Farcticbi

oscienceas%2Ffinancial-results-fy

-2021&sa=D&ust=1649157182461000&usg=AOvVaw3XfKkRo23hCmsUFKEIyIRt)

Participants will be required to register to view the webcast and participate in

the Q&A.

For more information, please contact

Christer L. Valderhaug

CEO Arctic Bioscience

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

nutraceutical and pharmaceutical products based on unique bioactive marine

compounds from herring roe.

The company is developing HRO350 - a novel investigational drug candidate based

on herring roe. HRO350 is being developed for treatment of patients with mild-to

-moderate psoriasis. This is a large patient group in need of new effective

medicines with beneficial safety profile.

Herring roe contains lipids that are essential in maintaining cell membranes and

omega -3 fatty acids that contribute to the normal functioning of brain, heart,

and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk

ingredients as well as finished goods under the ROMEGA® brand. The strategy is

to switch sales from bulk to finished goods and focus markets are USA and China.

Arctic Bioscience is led by a team of highly competent people with experience in

developing marine oils and experience from global pharmaceutical companies.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.